Berinert

Phase 3Small molecule

CSL Behring

Berinert is one of 50 small molecule programs targeting Kidney Transplant. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Kidney TransplantActive, not recruiting

AngioedemaActive, not recruiting

Kidney TransplantPhase 2

Active, not recruiting

AngioedemaPhase 3

Active, not recruiting

Competition

Competitive Landscape

476 competitors in Kidney Transplant

#DrugCompanyPhaseTrials

Nulojix

Bristol-Myers Squibb

Preclinical

16 2

Berinert

CSL Behring

Phase 3

1 3

Zemplar

AbbVie

Preclinical

2 4

Sensipar

Amgen

Preclinical

1 5

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

1 6

Cysteine Hydrochloride

Novartis

Preclinical

1 7

Jardiance

Boehringer Ingelheim

Preclinical

3 8

Nydrazid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

2 9

Truphylline

TThe Searle Company Limited Pakistan

Preclinical

1 10

Cytovene

EExela Pharma Sciences, LLC.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2032

Phase 2Recruiting

Kidney Transplant

NCT06919003

Clinical

Trials by Indication[1]

Tics1 trial

A Study to Evaluate the Safety and Pharmacokinetics of Two Formulations of C1-esterase Inhibitor

Completed· CSL Behring logo

CSL Behring·Phase 1·NCT01760343·16 enrolled

Kidney Transplant1 trial

Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE TRIAL)

Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT06919003·180 enrolled

Angioedema1 trial

Randomized, Double-blind, Two Arms, Multicenter, Phase III Study of Berinert for Treatment of ACE Induced Angioedema

Completed·TTechnical University of Munich·Phase 3·NCT01843530·31 enrolled

GIST1 trial

Patient Registry Study of Berinert® in Normal Clinical Practice

Completed· CSL Behring logo

CSL Behring··NCT01108848·318 enrolled

Unspecified1 trial

Berinert (C1INH) vs Placebo for DGF/IRI

Completed·—·Phase 1/2·NCT04696146·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Berinert. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Berinert compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Berinert. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CSL Behring company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CSL Behring

Berinert

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2032

Trials by Indication[1]

Tics1 trial

Kidney Transplant1 trial

Angioedema1 trial

GIST1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News